




AGENT™ Small Vessel Study



A Japanese multicenter, prospective, randomized, non-inferiority study comparing AGENT vs. SeQuent Please™ in SV & de novo lesions.

AGENT™ Japan Small Vessel Study Design



Primary Endpoint: 6-month TLF (cardiac death, TV-MI, or TLR). Follow-up at 6 months & up to 5 years

Primary Endpoint: This trial meets its primary endpoint and non-inferiority achieved despite lower balloon drug load – AGENT 2 µg/mm², SeQuent Please 3 µg/mm².*



AGENT demonstrated numerically lower levels of late lumen loss compared to SeQuent Please.

* Results for the Small Vessel RCT study.
1 Nakamura M, Isawa T, Nakamura S, et al. Drug-Coated Balloon for the Treatment of Small Vessel Coronary Artery Disease – A Randomized Non-Inferiority Trial –. Circ J. 2023;87(2):287-295.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material is not intended for use in France. IC-2411604-AA ©2026 Boston Scientific Corporation or its affiliates.

